Efficacy and Safety of SBRT Followed by Tislelizumab Plus Cetuximab and Irinotecan in Patients With Previously Treated RAS Wild-type Advanced Refractory Colorectal Cancer
Clinical trial NCT05799443 · UNKNOWN
Trial details
- NCT number
- NCT05799443
- Sponsor
- Fujian Cancer Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-04-05
- Primary completion
- 2024-04-05
- Enrollment
- 23
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.